-
Target
Degradation -
Wide
Applicable -
New
Paradigm

We believe that the elimination of these disease-causing aggregates will provide a fundamental and novel cure for Alzheimer's disease.

AUTOTACs can selectively degrade KRas and target mutant p53 aggregates for autophagic degradation, which we believe can be used to cure a wide spectrum of cancers.

Diseases
By synthetically activating lipophagy, our ATL
compounds can promote intrinsic breakdown of
fatty lipids and glucose level regulation and
thereby treat metabolic diseases.
We believe that promoting selective autophagy
via our ATL compounds will provide a novel
therapeutic avenue for both glucose level regulation
and lipid breakdown for type 2 diabetes.

Dystrophy
Our autophagy-regulating compounds can inhibit the excessive degradation of actin and other cytoskeletons, thereby halting muscle wasting as a potential cure for Duchene muscular dystrophy.

We believe targeted protein degradation of amyloidogenic aggregates can counteract the pathological tissue deposits essential to amyloidosis.
Molecule Medicine and Biopharmaceutical Sciences Department. Graduate School of Convergence Science & Technology. Professor of Seoul National University, Korea
-
10
2021.06
’20 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PRE..
’20 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING,AMELIORATING, OR TREATING PROTEINOPATHIES ..
more -
10
2021.06
’20 P62 LIGAND COMPOUND AND ER-PHAGY-PROMOTING USE THEREOF (KR, WO)
’20 P62 LIGAND COMPOUND AND ER-PHAGY-PROMOTING USE THEREOF (KR, WO)Provided are a composition for promoting ER-phagy, a ..
more -
10
2021.06
’19 NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSIT..
’19 NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING,OR TREATING DISEAS..
more -
10
2021.06
’19 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIA..
’19 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING,OR TREATING PROTEINOPATHIES COMPRISING SAME..
more -
10
2021.06
'19 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TR..
'19 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING ORTREATING OBESITY OR METABOLIC SYNDROME COMPRISING S..
more -
10
2021.06
’15 PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH AUT..
’15 PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH AUTOPHAGY ACTIVITY MEDIATED BY LIGAND OR ARGINYLATED ..
more -
08
2021.06
’13 METHOD FOR REGULATING P62 ZZ DOMAIN-MEDIATED AUTOPHAGY AND USE THE..
’13 METHOD FOR REGULATING P62 ZZ DOMAIN-MEDIATED AUTOPHAGY AND USE THEREOF (KR, WO)The present invention relates to: a..
more
-
09
2021.06
Group-ware Introduction (2021.03.08)
AUTOTAC Bio Inc. Group-ware Introduction (2021.03.08.)
more -
09
2021.06
Establishment and publication of company regulations (2021.03.02.)
Establishment and publication of company regulation (2021.03.02.)
more -
09
2021.06
Establishment of R&D Center (2021.01.08.)
Establishment of R&D Center (2021.01.08.)
more
(C) 2021. AUTOTAC Bio Inc. All rights reserved.